Hybridan Small Cap Feast: 17/04/2025

* A corporate client of Hybridan LLP

** Potential means Intention to Float (ITF) has been announced, or it is a rumour

***Arranged by type of listing and date of announcement

****Alphabetically arranged

Share prices and market capitalisations taken from the current price on the day of publication

Dish of the day

 

Admissions:  


Delistings:  

Kingswood Holdings (KWG.L) has left AIM.

What’s baking in the oven?

Potential**  Initial Public Offerings:

18th March: Uranium Energy Exploration, to be renamed The Smarter Web Company (AQSE:SWC) is a UK-based web design agency, specialising in creating bespoke, mobile-friendly websites and offers a range of online marketing strategies to help businesses enhance their online presence. Services include various web design packages, logo design, Search Engine Optimisation, animation and custom development. It is looking to do a fundraise of £2m on AQSE. Admission expected on or around 22nd April.  

Potential Market Movers:

17th April 2025: RentGuarantor (AQSE:RGG), the provider of rent guarantee services to prospective tenants across the socio-economic spectrum wishing to rent property in the UK private rental sector, announces its intention to move to AIM from AQSE.  The Board currently expects that Admission to trading on AIM would occur this Summer.
 

Banquet Buffet****

The lithium developer in Chile announced it is collaborating with DuPont Water Solutions, a business unit of DuPont, to test lithium processing technology. DuPont has developed a new nanofiltration membrane technology for high lithium recovery. This will be tested in CleanTech Lithium's direct lithium extraction downstream process.  CleanTech Lithium is investigating the potential of these technologies to eliminate the need for thermal evaporation and crystallisation in production of battery grade lithium carbonate, which would result in potentially significant CAPEX savings.

The global energy storage innovator announced an equity fundraising of up to £2.1m at 9p by way of a placing, subscription and retail offer.   The Issue Price represents a discount of approximately 12.2%.  The net proceeds of the Fundraising will be used to advance the Company's strategic partnership with the Max Planck Institute, business development workstreams, establishing corporate collaboration, expansion of the Company's Integration Solutions business, and for general working capital purposes.

The advanced materials Company announces that further to its announcement of 10 February 2025 regarding its wholly owned subsidiary, Haydale Ceramic Technologies (HCT) being placed into a corporate insolvency process under Chapter 11 and the proposed public auction of the business and assets of HCT, the auction process has now concluded. Greenleaf Corporation ultimately made the highest offer during the process, which has today been confirmed by the court, amounting to $680,000, though at this level the Board does not anticipate any cash being returned to the UK entities against its intercompany debtor balance.

The specialists in the exploration and production of iodine and manufacturers of specialty chemical products provides an update regarding its activities during Q1 2025.  In the Period, Iofina Resources produced 124.1 metric tonnes (MT) of crystalline iodine from its seven IOsorb plants in western Oklahoma (Q1 2024: 123.7MT).  Given the lower-than-anticipated Q1 2025 production, the Company now expects total iodine production for H1 2025 to be closer to 300MT compared to the previously guided range of 320MT-355MT. Prices and demand for raw iodine have remained strong, with the Company currently selling all crystalline iodine it is producing. The iodine spot price has been consistently above $70/kg in the Period, which is higher than the H2 2024 average price, and the Company expects prices to remain at these levels throughout 2025.

The gold exploration and development Company with projects in South Africa and the USA announced that the Company has raised £530,000 at 3.4p.  The net proceeds of the Fundraise are intended to be used by the Company for working capital and to support ongoing exploration activities and permitting across Lexington Gold's South African and USA gold projects.  Funds will also be used towards ongoing activities relating to the Jelani Resources Proprietary Limited joint venture with Harmony Gold Mining Company Limited as well as progressing the discussions with Gold One Africa Limited at the Ventersburg project.

The developer of clinical diagnostic solutions for lung cancer announces that it has entered into a conditional exclusive license and distribution agreement for the commercial distribution of its LungLB test in the US with Circulogene Theranostics, a US liquid biopsy diagnostics company.
Under the Agreement, an advanced payment of $375,000 will shortly be paid to LungLife by Circulogene following signature. Following Completion of the Agreement, a further payment of $375,000 is to be received by LungLife.  LungLife will receive royalty payments equivalent of twenty per cent of the net revenue collected by Circulogene in relation to the LungLB test for the first year of the Agreement, but with guaranteed minimum royalty payments covering the first three quarters of this year of $450,000, provided that, if the actual royalty payments earned in that period equate to less than $450,000, the shortfall will be offset against future royalty payments due under the Agreement.

The mathematical modelling, data science and biostatistics Company supporting the development of new therapeutics and personalised medicine solutions announced a contract award with a new UK client.
The project will involve the application of modelling and simulation techniques to support the development of a first-in-class bifunctional antibody therapy designed to target multiple solid tumour indications.  The project is valued at £47,600 and is projected to complete over the next three months.

The UK-based consultancy delivering high-impact engineering solutions to the defence sector's most critical platforms announces its unaudited half year results for the six months ended 28 February 2025.
Revenue was £3.8m in line with the Board's expectations, representing growth of 8% compared to the half year ended 29 February 2024 and 30% compared to the half year ended 31 August 2024.  The gross margin increased to 33% from 30% in the half year ended 29 February 2024 and 25% for the Full Year 2024.  Profit before tax of £0.6m, up 8% compared to the half year.  New contracts worth £2.3m have been booked as anticipated revenue for the financial year ending 31 August 2025. The current pipeline underpins the Board's confidence in meeting current market expectations for FY2025.

The greentech Company delivering lower fuel costs and emissions announced that it has secured a valuable patent from the African Regional Intellectual Property Organization (ARIPO) covering eight further countries.  The latest patent, designated in respect of Gambia, Ghana, Kenya, Mozambique, Sierra Leone, Uganda, Zambia and Zimbabwe, is a major development supporting SulNOx's pursuit of partnerships and collaborations with large industrial groups in the substantial African market.  

The Company focused on value creation from Internet of Things (IoT) technology businesses announces an underwritten Open Offer to raise approximately £340,140 (before expenses) at an Issue Price of 1.00p per Open Offer Share which represents a discount of approximately 28.6% to the closing middle market price of 1.40p for each Ordinary Share on 16 April 2025.  The Open Offer is open for acceptance from now until 6 May 2025.  

 

This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.

This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.

References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results.  Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.

In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.